«

»

6月 02

Selected original publications 2015

Selected original publications 2015年(平成27年)

Arato T, Daimon T, Heike Y, Ishii K, Itho K, Kageyama S, Kawakami Y, Nakayama E, Ozawa K, Sato N, Shiku H, Takeuchi M, Tani K, Tamada K, Ueda R, Yamaguchi Y, Yamanaka T, Yamaue H, Yasukawa M, Iguchi T, Kitano S, Miyahara Y, Nagata Y, Noguchi M, Terashima T, Asano T, Asonuma M, Ikeda H, Kakimi K, Takesako K, Tanaka M, Amakasu K, Yamada A, Harada N, Aoshi T, Kuroda E, Kobiyama K, Muraoka D, Yamazaki N, Kuchiba A, Tanaka S, Michimae H, Yamada T, Hanada K, Okada H, Takebe N, Hirano N, Okumura S, Sato D, Shibatsuji M, Yamaguchi T. 2015 Guidance on cancer immunotherapy development in early-phase clinical studiesCancer Sci. 106(12):1761-1771,2015


Ohmura G, Tsujikawa T, Yaguchi T, Kawamura N, Mikami S, Sugiyama J, Nakamura K, Kobayashi A, Iwata T, Nakano H, Shimada T, Hisa Y, Kawakami Y. Aberrant Myosin 1b Expression Promotes Cell Migration and Lymph Node Metastasis of HNSCC. Mol. Cancer Res. 13(4):721-731,2015


Ozasa H, Hazama S, Shimizu R, Etoh R, Inoue Y, Kanekiyo S, Shindo Y, Suzuki N, Takenouchi H, Tsunedomi R, Iizuka N, Yoshino S, Okuno K, Sugiura F, Fujita Y, Hamamoto Y, Fujita T, Kawakami Y, Nakamura Y, Oka M. miR-196b and miR-486 are possible predictive biomarkers for the efficacy of the vaccine treatment; from the results of phase I and II studies for metastatic colorectal cancer.ASCO. In Press:,2015

Namiki T, Yaguchi T, Nakamura K, Valencia JC, Coelho SG, Yin L, Kawaguchi M, Vieira WD, Kaneko Y, Tanemura A, Katayama I, Yokozeki H, Kawakami Y, Hearing VJ. NUAK2 amplification coupled with PTEN deficiency promote melanoma development via CDK activation. Cancer Res.  75(13):2708-2715,2015

Kawakami Y, Qian L, Kawamura N, Miyazaki J, Tsubota K, Kinoshita T, Nakaura K, Ohmura G, Satomi R, Sugiyama J, Nishio H, Hayakawa T, Popivanova B, Nuchsupha S, Liu TH, Kamijuku H, Kudo-Saito C, Tsukamoto N, Sakurai T, Fujita T, Yaguchi T. Cancer Induced Immunosuppression and its Modulation by Signal Inhibitors in “Resistance of cancer cells to CTL-mediated immunotherapy” Eds: Chouaib S and Bonavida B, Springer.hapter 13(総頁351):287-302,2015

Yamaguchi S, Ueki A, Sugihara E, Onishi N, Yaguchi T, Kawakami Y, Horiuchi K, Morioka H, Matsumoto M, Nakamura M, Muto A, Toyama Y, Saya H, Shimizu T.  Synergistic antiproliferative effect of imatinib and adriamycin in PDGF receptor–expressing osteosarcoma cells. Cancer Sci. 106(7):875-82,2015

Kawakami Y, Qian L, Kawamura N, Miyazaki J, Nagumo H, Tsubota K, Kinoshita , Nakamura K, Ohmura G, Satomi R, Sugiyama J, Nishio H, Hayakawa T, Popivanova B, Nuchsupha S, Liu TH, Kamijuku H, Kudo-Saito C, Tsukamoto N, Sakurai T, Fujita T, Yaguchi T. Development of personalized combination cancer immunotherapy based on the patients’ immune status in “Inflamamtion and immunity in cancer ”  Eds:Tsukasa Seya, Keiko Udaka, Misako Matsumoto, Noriyuki Sato, Springer. Chapter 20(総頁268):255-266,2015

Katano I, Takahashi T, Ito R, Kamisako T, Mizusawa T, Ka Y, Ogura T, Suemizu H, Kawakami Y, Ito M. Predominant Development of Mature and Functional Human NK Cells in a Novel Human IL-2–Producing Transgenic NOG Mouse. J Immunol.194(7):3513-25,2015

Mayanagi S, Kitago M, Sakurai T, Matsuda T, Fujita T, Higuchi H, Taguchi J, Takeuchi H, Itano O, Aiura K, Hamamoto Y, Takaishi H, Okamoto M, Sunamura M, Kawakami Y, Kitagawa Y. Phase I pilot study of Wilms tumor gene 1 peptide-pulsed dendritic cell vaccination combined with gemcitabine in pancreatic cancer.Cancer Science. 106(4):397-406,2015